Monitoring and Management of Entresto (Sacubitril/Valsartan) in Adult CKD Patients

Monitoring Parameters Within 2–4 Weeks of Initiation or Dose Increase

Criteria for Discontinuing or Holding Therapy

Dose Optimization Guidance

Management of Mild eGFR Declines

Hyperkalemia Management Strategy